Search Results (73)

Background: Partial nephrectomy (PN) is the standard treatment for localized renal tumors where nephron preservation is feasible. The evolution of minimally invasive surgery has progressed from conventional two-dimensional laparoscopy to three-dimensional (3D) laparoscopy and, more recently, to robotic-assisted techniques. Although robotic and laparoscopic PN have been widely compared, evidence focusing on a complete transition from 3D laparoscopy to robot-assisted partial nephrectomy (RAPN) remains scarce. Methods: This retrospective single-surgeon study included 80 consecutive patients treated between 2018 and 2024, encompassing the full transition period from 3D LPN to RAPN. Thirty-six patients underwent 3D laparoscopy and forty-four underwent robotic surgery, excluding the first ten robotic cases representing the learning phase. Propensity score weighting was applied to minimize baseline differences. Results: Tumors treated with RAPN had significantly higher RENAL scores (median 8 vs. 6, p = 0.001), indicating greater complexity, while perioperative outcomes—including hospital stay, operative time, and complication rates—remained comparable. Warm ischemia time was significantly shorter in the RAPN group (17.5 vs. 22 min, p = 0.005), and the TRIFECTA rate was higher though not statistically significant. Conclusions: These results indicate that a complete transition from 3D laparoscopy to robotic partial nephrectomy is safe and feasible, maintaining or improving outcomes even in more complex tumors and broadening the applicability of nephron-sparing surgery. Full article

Background: Liver transplantation (LT) continues to evolve with techniques aimed at minimizing perioperative complications associated with caval and portal vein clamping. Caval-sparing approaches, such as the piggyback technique, preserve hemodynamic stability; however, portal clamping remains necessary and may trigger postreperfusion syndrome, endotoxemia, and hepatic microcirculatory disturbances. Temporary portocaval shunts (PCSs) have been developed to maintain portal flow during LT, mitigating these adverse effects and allowing for hemodynamic stability and a reduced intraoperative bleeding. Portocaval Shunts: Various PCS techniques—including end-to-side, right-branch, portosaphenous, mesenterico-saphenous, iliac-venous conduit interposition, portoumbilical, and Rex-saphenous shunts—allow an individualized approach based on patient anatomy and surgical complexity. Review of Evidence: Available evidence demonstrates that PCS improves intraoperative hemodynamic stability, reduces blood transfusion requirements, and preserves renal function, particularly in patients with high portal flow or severe portal hypertension. PCS may also shorten warm ischemia time, facilitate hepatectomy, and enhance outcomes in extended criteria donor grafts or marginal organs. Meta-analyses and randomized studies support its role in reducing intraoperative blood loss, improving early graft function, and accelerating postoperative recovery. However, the effect of PCS on long-term survival and major postoperative morbidity remains variable, likely due to heterogeneity in patient populations, donor types, and perioperative management. Conclusions: Overall, PCS represents a safe and feasible adjunct in LT, offering significant hemodynamic and technical advantages. Its use should be individualized based on patient risk factors, intraoperative hemodynamics, and anticipated intraoperative challenges. PCS provides a practical strategy to preserve portal flow, minimizing intraoperative complications and facilitating the hepatectomy. However, the decision to create a PCS during LT still depends on the surgeon’s preference. Postoperative outcomes and impact on long-term survival require further investigation. Full article

Background: Minimally invasive techniques for living donor nephrectomy are crucial for donor safety and promoting organ donation. Hand-Assisted Retroperitoneoscopic Donor Nephrectomy (HARP-DN) combines the benefits of minimally invasive surgery with the tactile feedback of open surgery. This study analyzes a single center’s initial experience with this technique. Methods: A retrospective analysis was conducted on the first 50 consecutive living kidney donors who underwent HARP-DN at our institution. We collected and evaluated preoperative demographics, intraoperative data (operating time, warm ischemia time), and postoperative outcomes, including complication rates, length of hospital stay, and donor renal function at discharge. Results: All 50 HARP-DN procedures were successfully completed with zero conversions to open surgery and no donor mortality. The mean operating time was 192.4 ± 57.7 min, and the median warm ischemia time was a competitive 110 s. The overall perioperative complication rate was low at 4% (2/50 cases), involving manageable bleeding events. Donors experienced a rapid return to oral diet, and all were discharged with excellent renal function as indicated by a mean serum creatinine of 1.09 ± 0.30 mg/dL. Conclusions: Our initial experience demonstrates that Hand-Assisted Retroperitoneoscopic Donor Nephrectomy is a safe, reproducible, and effective procedure. It offers the advantages of a minimally invasive approach, including low morbidity and excellent preservation of donor renal function, while achieving a short warm ischemia time critical for graft quality. These findings support HARP-DN as a safe, reproducible, and effective option for living donor nephrectomy. Full article

Background/Objectives: We aimed to evaluate the feasibility and safety of a combined approach to partial nephrectomy, which involves laparoscopic dissection for kidney as well as renal hilum mobilization, followed by robotic assistance for tumor resection and intracorporeal suturing, integrating the technical advantages of both laparoscopic and robotic surgery. Methods: We retrospectively analyzed 99 patients with clinical stage 1 renal tumors who underwent laparoscopic (LPN, n = 31), robot-assisted (RAPN, n = 16), or combined partial nephrectomy (CPN, n = 52) between 2016 and 2024. CPN involved laparoscopic mobilization of the kidney and renal hilum, followed by robotic tumor excision and intracorporeal suturing. Perioperative and postoperative outcomes were compared across groups. Results: Comparative analysis of the demographic characteristics of patients who underwent LPN, RAPN and CPN revealed no significant differences. The mean operative time (OT) was 126.75 ± 25.28 min for CPN, 121.9 ± 9.5 min for LPN (p = 0.014), and 155.5 ± 18.03 min for RAPN (p < 0.001). The median warm ischemia time (WIT) was 20.0 min (10.0–26.0) for CPN, which is comparable to RAPN at 18.5 min (14.0–23.0) (p = 0.158), but it was significantly longer for LPN at 23.0 min (18.0–28.0) (p < 0.001). The estimated blood loss (EBL) was 120.0 mL (50.0–350.0) for CPN, which is similar to RAPN at 110.0 mL (50.0–300.0) (p = 0.158), while it was higher for LPN at 180.0 mL (100.0–250.0) (p < 0.001). No major intraoperative or postoperative complications classified as Clavien–Dindo grade ≥3 were observed in any group. Conclusions: CPN is a feasible and safe approach for clinical stage 1 renal tumors, combining the efficiency of laparoscopy with the precision of robotics. Compared with LPN and RAPN, CPN showed comparable early oncological and functional results and had shorter operative duration and improved perioperative parameters. Full article

Background: Kidney transplantation activity at the University Hospital of Guadeloupe was briefly interrupted at the onset of the COVID-19 pandemic, reflecting the global impact of this health crisis on organ transplantation. This study assessed patient and graft recovery in 335 recipients transplanted between 2013 and 2023, comparing those transplanted before 2020 and after the resumption of activity. The objective was to evaluate changes in recipient profiles, surgical parameters, and post-transplant outcomes following this disruption. Methods: This retrospective cohort included all kidney transplants performed at the University Hospital of Guadeloupe over a ten-year period. Most patients (70%) received transplants before 2020, with 30% afterward. All grafts were ABO-compatible, and 98.2% were from deceased donors. Trends in transplant activity were analyzed to identify variations over time, with a peak observed in 2018, followed by a decline until 2021 and a progressive recovery from 2022. Comparative analyses were performed to examine disparities in donor and recipient characteristics, ischemia durations, and outcomes between the two periods. Results: After 2020, recipients were more likely to be elderly (≥70 years), immunized, obese, have heterozygous sickle cell disease, or have polycystic kidney disease (p < 0.05). Mean cold ischemia time decreased (p = 0.009), while warm ischemia time increased (p < 0.001), reflecting procedural and logistical adaptations. Graft survival remained stable, with 97.5% at 6 months and 89.8% at 4 years for transplants before 2020, versus 100% and 96.9%, respectively, after 2020 (p = 0.160). Patient survival did not differ significantly between periods (p = 0.199). Independent factors associated with mortality included recipient age ≥ 60 years, diabetes, graft failure, transplantation before 2020, cold ischemia time ≥ 1200 min, and graft pyelonephritis. Conclusions: Despite the temporary suspension of activity and an increased proportion of transplants with expanded criteria after 2020, graft recovery and patient survival were not adversely affected. These findings suggest that kidney transplantation in Guadeloupe demonstrated strong resilience and capacity for adaptation during and after the COVID-19 crisis, maintaining outcomes comparable to the pre-pandemic period. Full article

Background and Objectives: The use of controlled donation after circulatory death (cDCD) donors has significantly increased during the past decades and successfully expanded the donors’ pool. However, warm ischemia may have detrimental effects on graft function. Italian Law requires a no-touch period of at least 20 min, which is much longer compared to the 5 min accepted in most European countries. Materials and Methods This is an Italian single-centre retrospective review of all cDCD procedures performed from April 2021 to June 2025. Patients with severe brain injury undergoing withdrawal of life-sustaining therapy (WLST) were considered for cDCD. After cardiac arrest and a no-touch period of 20 min, organ reperfusion was performed using abdominal or thoraco-abdominal normothermic regional perfusion (NRP) through femoral vessels cannulation. The primary endpoint was 30-day graft survival; secondary endpoints included: incidence of primary non-function (PNF) and non-anastomotic biliary stricture (NAS) in liver transplantation, PNF and delayed graft function (DGF) in kidney transplantation, primary graft dysfunction (PGD) in heart and lung transplantation, and recipient’s survival. Results: A total of 52 patients, 33 (63%) males, median age 74 (65–79) years, underwent WLST during the study period and were included in the cDCD program. Median functional warm ischemic time (WIT), total WIT, asystolic phase, and NRP duration were 37 (34–40), 40 (37–42), 24 (23–26), and 192 (166–212) min, respectively. A total of 123 organs (46 livers, 61 kidneys, 8 hearts, and 8 lungs) were considered suitable for transplantation, procured, and successfully transplanted in 115 recipients. We report the early and mid-term outcomes of 84 recipients, including 41 liver recipients, 32 kidney recipients, and 8 heart recipients transplanted at the Azienda Ospedaliera Universitaria Integrata of Verona, and 3 lung recipients transplanted at the Azienda Ospedale Università of Padova. The 30-day graft survival was 95% in liver recipients, 97% in kidney recipients, and 100% in heart and lung recipients. PNF was observed in two liver recipients, and PGD in two lung recipients. DGF was recorded in 3 (9%) kidney recipients. Six recipients died during the follow-up, and the mean survival time was 3.9 ± 0.1 years. Conclusions: Solid organ transplantation using cDCD donors is feasible and provides excellent early and mid-term results despite longer donor asystolic times. Larger data and longer follow-up are necessary to confirm these promising results. Full article

(1) Background: We propose that cfDNA levels may serve as a valuable biomarker for monitoring the progress of liver transplant recipients, reflecting the quality of the donated organ, and predicting patient prognosis and survival. Thus, we analyzed the relationship between total cfDNA levels during the first 48 h post-transplantation, ischemia–reperfusion injury, and patient outcomes. (2) Methods: cfDNA quantification was applied to 115 liver transplant patients using real-time quantitative PCR at the time of transplantation (during reperfusion) and throughout the first month post-transplantation. (3) Results: Significantly higher early cfDNA levels were observed in patients who suffered liver damage or post-transplantation complications during the first month. High cfDNA levels were also associated with prolonged ICU stays and reduced survival. Kaplan–Meier analysis revealed a significantly lower survival rate in patients with elevated cfDNA. CRP levels were elevated and significantly correlated with cfDNA values. Regarding organ preservation prior to transplantation, prolonged cold and warm ischemia times were significantly associated with high cfDNA levels in the early hours post-transplantation. (4) Conclusions: Elevated cfDNA levels in the early hours following liver transplantation are associated with poorer patient outcomes. Therefore, determining total cfDNA levels post-transplantation may be a valuable tool for patient management and early intervention. Full article

Background: Uncontrolled donation after circulatory death (uDCD) remains underutilized globally, despite critical organ shortages. We report outcomes from Israel’s uDCD kidney transplant program compared with the matched donation after brain death (DBD) recipients. Methods: This retrospective cohort study analyzed all uDCD kidney transplants performed at the Rabin Medical Center between January 2018 and December 2024, compared with DBD transplants during the same period. Propensity score matching (1:3 ratio) was performed using recipient demographics, comorbidities, and donor characteristics. Primary outcomes included delayed graft function (DGF), graft failure, and patient survival. Results: Among 92 kidney transplants, 21 (22.8%) were from uDCD donors. After propensity-matching (21 uDCD, 63 DBD), significant baseline differences persisted: uDCD recipients were younger (47.2 ± 11.8 vs. 57.5 ± 10.9 years, p < 0.001) despite a similar dialysis vintage (7.2 ± 3.2 vs. 7.7 ± 3.7 years, p = 0.569). Warm ischemia time was 58.5 ± 12.3 vs. 3.0 ± 0.0 min (p < 0.001), and cold ischemia time was longer in uDCD (13.7 ± 5.9 vs. 8.4 ± 2.5 h, p < 0.001). DGF occurred in 90.5% of uDCD versus 54.1% of DBD recipients (p = 0.006). Graft failure was markedly higher in uDCD (28.6% vs. 1.6%, p = 0.001), yet mortality was lower (14.3% vs. 27.9%, p = 0.339). After a median follow-up of 60 months (IQR 48–72) for both groups, the death-censored 5 year graft survival rate was 71.4% for uDCD versus 98.4% for DBD (p < 0.001). Conclusions: Despite higher rates of DGF and graft failure, uDCD kidney transplantation demonstrated an acceptable 5 year patient survival rate in carefully selected younger recipients. These findings support cautious expansion of uDCD programs with rigorous recipient selection criteria and realistic outcome expectations. Full article

Background: Robot-assisted partial nephrectomy (RAPN) is a standard approach for localized renal cell carcinoma (RCC), emphasizing renal functional preservation. The Minimum Layer Resection (MLR) method, guided by 3D virtual partial nephrectomy (3DvPN) planning, was developed to balance oncological safety with parenchymal preservation. This study evaluated functional and oncological outcomes of RAPN with MLR and identified predictors of renal functional decline. Methods: We retrospectively analyzed 237 patients (after screening 312 cases) who underwent RAPN between 2012 and 2022 with ≥36-month follow-up. 3DvPN planning was used to guide MLR when feasible; both MLR and non-MLR were available and applied throughout the study period according to predefined indications. The primary endpoint was the percentage of estimated glomerular filtration rate (eGFR) preservation at 36 months; a ≥10% decline was clinically significant. Secondary endpoints included perioperative outcomes, acute kidney injury (AKI), and oncological outcomes such as margin involvement and recurrence. Results: The median age was 60 years, tumor size 29 mm, and warm ischemia time 21 min, with selective or superselective clamping achieved in 62.8% of cases. Postoperative AKI occurred in 25.0% (no patient required dialysis). At 3 years, the median eGFR preservation rate was 84.4%, and 28.5% of patients experienced a ≥10% decline. Independent predictors of short-term decline (14 days) were BMI > 25 kg/m², AKI, and WIT > 25 min, whereas long-term decline (36 months) was associated with tumor size > 30 mm and WIT > 25 min. Margin involvement was 1.7%, recurrence 3.8%, and major complications (Clavien–Dindo ≥IV) occurred in 1.7%. Conclusions: In conclusion, RAPN with the MLR technique under 3DvPN guidance demonstrated favorable perioperative outcomes, acceptable oncologic safety, and good mid-term renal functional preservation (up to 36 months). The approach provides a reproducible surgical strategy that maximizes parenchymal preservation while maintaining negative surgical margins. Prospective multicenter studies with longer follow-up are warranted to confirm long-term durability and to define the role of MLR in routine practice. Full article

Background/Objectives: A novel treatment of absolute uterine factor infertility is uterus transplantation. In preparation for human surgery, autotransplantation was performed in a sheep model to assess ischemia-reperfusion injury of the uterine wall. Methods: Seven multiparous ewes underwent live-donor uterus autotransplantation; in six, the procedure was completed successfully. Tissue blocks of complete uterine wall, endometrium, and myometrium were obtained at four predefined time points: native (baseline), after 1 h of cold ischemia, after 30 min of warm ischemia, and after 30 min of reperfusion. Samples were analyzed by differential scanning calorimetry and routine hematoxylin–eosin histology. Results: Histology demonstrated preserved epithelial, glandular, and stromal structures, with only minimal, reversible changes that increased with the ischemic duration. Differential scanning calorimetry confirmed alterations in thermal stability: in the uterine wall and myometrium, the calorimetric enthalpy decreased from baseline (3.40 ± 0.53 J/g) to reperfusion (2.62 ± 0.22 J/g), indicating structural loosening; in contrast, the endometrium calorimetric enthalpy slightly increased, suggesting greater flexibility and less susceptibility to ischemia-reperfusion injury. Conclusions: In this preliminary study, differential scanning calorimetry proved to be an effective and sensitive method for detecting early structural alterations in the uterine wall that could negatively impact post-transplant function. Cold and warm ischemia did not cause irreversible damage within a two-hour time frame, supporting the feasibility of short-term preservation in uterus transplantation. The myometrium demonstrated more significant vulnerability than the endometrium, which highlights the necessity of protective strategies to preserve smooth muscle integrity during transplantation. Full article

Background and Objectives: Partial nephrectomy is the standard treatment for small renal tumors, balancing cancer control with renal function preservation. Robot-assisted partial nephrectomy (RAPN) has improved surgical precision and reduced morbidity. Near-infrared fluorescence (NIRF) imaging with indocyanine green (ICG) improves intraoperative visualization of renal vasculature and tissue perfusion, potentially enabling selective arterial clamping to reduce ischemic injury. This study updates contemporary evidence on NIRF/ICG-guided RAPN, focusing on intraoperative, perioperative, and renal function outcomes. Materials and Methods: We systematically queried PubMed, Scopus, and Web of Science databases up to June 2025 for controlled prospective and retrospective studies comparing NIRF/ICG-guided RAPN (selective clamping or zero-ischemia) versus conventional RAPN with main artery clamping in adults with renal masses. Data were synthesized narratively, and random-effects meta-analyses were performed on warm ischemia time (WIT), operative time, estimated blood loss, transfusion rate, length of hospital stay, complication rate, positive surgical margins, and variation in renal function. Results: Eleven studies (10 full-text and one abstract), including two randomized controlled trials, encompassing a patient population of 893 patients (403 NIRF/ICG-guided RAPN and 490 conventional RAPN), were included. Ischemia strategies varied between no clamping, selective or super-selective clamping for NIRF/ICG, and main artery clamping for controls. ICG doses ranging from 3 to 7.5 mg or 0.5–7 mL. Most evidence was classified as level 2b or 3b, indicating a moderate to serious risk of bias. Meta-analysis showed that compared to conventional RAPN, NIRF/ICG-guided RAPN was associated with a shorter WIT (MD: −1.30 min, 95% CI: −2.51 to −0.09; p = 0.039), with no differences in other outcomes. Renal function favored NIRF/ICG at discharge and short-term follow-up, although the difference was not statistically significant. Conclusions: NIRF/ICG reduces WIT during RAPN without increasing perioperative risks. The technique shows promise for better preserving functional outcomes. However, further well-designed, large-scale trials with longer follow-up are needed to confirm these benefits and define clinical indications. Full article

Background/Objectives: This systematic review aims to synthesize recent studies on the integration of artificial intelligence (AI) into robotic surgery for oncological patients. It focuses on studies using real patient data and AI tools in robotic oncologic surgery. Methods: This systematic review followed PRISMA guidelines to ensure a robust methodology. A comprehensive search was conducted in June 2025 across Embase, Medline, Web of Science, medRxiv, Google Scholar, and IEEE databases, using MeSH terms, relevant keywords, and Boolean logic. Eligible studies were original research articles published in English between 2024 and 2025, focusing on AI applications in robotic cancer surgery using real patient data. Studies were excluded if they were non-peer-reviewed, used synthetic/preclinical data, addressed non-oncologic indications, or explored non-robotic AI applications. This approach ensured the selection of studies with practical clinical relevance. Results: The search identified 989 articles, with 17 duplicates removed. After screening, 921 were excluded, and 37 others were eliminated for reasons such as misalignment with inclusion criteria or lack of full text. Ultimately, 14 articles were included, with 8 using a retrospective design and 6 based on prospective data. These included articles that varied significantly in terms of the number of participants, ranging from several dozen to several thousand. These studies explored the application of AI across various stages of robotic oncologic surgery, including preoperative planning, intraoperative support, and postoperative predictions. The quality of 11 included studies was very good and good. Conclusions: AI significantly supports robotic oncologic surgery at various stages. In preoperative planning, it helps estimate the risk of conversion from minimally invasive to open colectomy in colon cancer. During surgery, AI enables precise tumor and vascular structure localization, enhancing resection accuracy, preserving healthy tissue, and reducing warm ischemia time. Postoperatively, AI’s flexibility in predicting functional and oncological outcomes through context-specific models demonstrates its value in improving patient care. Due to the relatively small number of cases analyzed, further analysis of the issues presented in this review is necessary. Full article

Background: Robotic partial nephrectomy (RPN) for posterior renal tumors can be performed via the transperitoneal approach (TA); however, it may provide suboptimal visualization of posterior lesions compared to the retroperitoneal approach (RA). The camera port swapping (CPS) technique was developed to enhance intraoperative visualization and robotic arm maneuverability during TA-RPN. Methods: We conducted a retrospective review of patients who underwent RPN for posterior renal tumors between 2018 and 2024 using either TA with the CPS technique (n = 35) or RA (n = 29). All procedures used the da Vinci Xi surgical system, and the CPS technique involved repositioning the camera port intraoperatively when standard visualization proved inadequate during TA. Propensity score matching (1:1) was performed based on tumor size and body mass index to compare outcomes (n = 21 in each group). Results: Propensity score-matching analysis revealed that body mass index, tumor size, and RENAL nephrometry score were comparable between the two groups. The positive surgical margin was zero in all patients. The warm ischemia time was 22 min (0–44 min) in the TA-CPS group and 18 min (7–45 min) in the RA group (p = 0.504). No complications of Clavien–Dindo classification grade > 3 occurred in the TA-CPS group, while one occurred in the RA group (p = 1.000). Renal function decline was 4.8% in the TA-CPS group and 19% in the RA group (p = 0.343). Trifecta achievement rates were also comparable: 95.2% in the TA-CPS group and 81.0% in the RA group (p = 0.343). Conclusions: Camera port swapping during TA-RPN provided adequate visualization and perioperative outcomes comparable to those achieved with RA-RPN. This may be a practical alternative, particularly for anatomically complex posterior tumors. Full article

Background/Objectives: This study aimed to evaluate and compare the perioperative outcomes of robot-assisted partial nephrectomy (RAPN) for complex renal tumors performed using the novel Japanese Hinotori Surgical Robot System (HSRS) and the established Da Vinci Surgical System (DVSS). Methods: Of 484 consecutive patients who underwent RAPN at our institution, 126 with complex renal tumors were included in the DVSS group, and 48 such patients were included in the HSRS group. Complex tumors in this series were defined by the presence of at least one of the following factors: cT1b, completely endophytic, hilar, cystic, or ipsilateral multiple tumors. Results: Following 1:2 propensity score matching, 74 and 37 patients were included in the DVSS and HSRS groups, respectively. Post-matching, most covariates’ absolute standardized mean difference (SMD) was less than 0.1, indicating effective baseline imbalance correction. All RAPN procedures using HSRS were completed without conversion to open surgery, nephrectomy, or Clavien–Dindo ≥3 postoperative complications. No significant differences in major perioperative outcomes were observed between DVSS and HSRS, including operative time (178 vs. 186 min), console time (115 vs. 115 min; encompassing cockpit time for HSRS), warm ischemia time (15 vs. 15 min), and estimated blood loss (51 vs. 30 mL). Positive surgical margin rates (DVSS 1.4% vs. HSRS 5.4%) and Trifecta achievement rates (94.6% vs. 91.9%) were also comparable, with no significant differences. Conclusions: These findings suggest that, even in patients with complex renal tumors, RAPN performed using the HSRS can achieve perioperative outcomes comparable to those obtained with the established DVSS. Full article

The need for organs suitable for transplantation has continued to rise as need outweighs availability. Increased demand has driven innovation in the field. Over the past ten years, donation after circulatory death (DCD) donors have become a greater portion of the donor pool. This method of donation includes a period of warm ischemia time to the organs. Thus, its use is dependent on recovery methods. Historically, extracorporeal membrane oxygenation (ECMO) was one of the first pumping technologies to enhance organ preservation in the potential donor. Subsequently, the adoption of normothermic regional perfusion (NRP) technology has also shown promise in organ transplantation. These technologies have increased utilization of organs and enhanced the pool of donor organs. This review seeks to summarize the literature supporting in situ technologies (ECMO and NRP) utilized in procurement of solid organs from DCD donors. The benefit of in situ perfusion in DCD organ recovery is that these technologies increase the number of organs available for transplantation by reducing ischemic injury. The disadvantages include the added technical aspect, added operating room time, and the increased ethical concerns surrounding these technologies compared to conventional methods of organ recovery. Full article